Interestingly, after anti-PD-L1 treatment, survival was longer in WT mice than in B cell KO mice, indicating that B cells enhance anti-PD-L1 antibody activity, but after anti-CTLA-4 treatment, there was no difference in survival between WT mice and B cell KO mice (Figures 1A, B) In addition, we found more tumor-specific CD8+ T cells in anti-PD-L1-treated WT mice than in anti-PD-L1-treated B cell KO mice (Figure 1C). The gene discussed is CTLA4; the disease is neoplasm.